癌症免疫治疗中的仿生与个体化纳米疫苗：设计创新、转化挑战与未来方向

Personalized nanovaccines represent advancing frontier in cancer immunotherapy by integrating patient-specific tumor antigens with biomimetic delivery systems to enhance immune activation, targeting precision and clinical efficacy. Biomimetic platforms including exosome-, red blood cell (RBC)-, and immune cell membrane-coated nanoparticles, as well as artificial antigen-presenting cell (aAPC) systems, recreate native biological interfaces to improve antigen presentation, macrophage polarization, and adaptive immune priming. Despite significant progress, major translational challenges remain, including incomplete mechanistic understanding, regulatory complexity, and manufacturing scalability. This review synthesizes recent advances in biomimetic and personalized nanovaccine design, highlighting clinical progress in lipid nanoparticle (LNP)-based vaccines such as BNT111 and mRNA-4157, emerging innate immune adjuvants including Toll-like receptor (TLR) and stimulator of interferon genes (STING) agonists, and rational combination strategies with immune checkpoint blockade. Key safety and quality consideration including immunotoxicity, off-target immune activation, and batch heterogeneity are critically evaluated alongside emerging engineering solutions. Finally, future directions integrating AI-guided neoantigen prediction, modular microfluidic manufacturing, and multi-omic biomarker frameworks are discussed to accelerate next generation cancer nanovaccine translation.